Merus N.V. Announces Pricing of Public Offering of Common Shares
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced the pricing of an underwritten public offering of 5,263,158 common shares, at a public offering price of $57.00 per share (the “Offer Shares”). Merus also granted the underwriters a 30-day option to purchase up to an additional 789,473 common shares (the “Option Shares” and together with the Offer Shares, the “Shares”). The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses and excluding the underwriters' option to purchase the Option Shares, are expected to be approximately $300.0 million. All of the shares in the offering are to be sold by Merus.
Merus to Present at Upcoming Investor Conferences
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
Merus Announces the Journal Publication of Petosemtamab Mechanism of Action
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
Merus to Present at BofA Securities 2025 Health Care Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates
Merus N.V. (MRUS) came out with a quarterly loss of $1.40 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $0.59 per share a year ago.
Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update
- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update at 2025 ASCO® Annual Meeting
Earnings Preview: Merus N.V. (MRUS) Q1 Earnings Expected to Decline
Merus (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting
- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim clinical data selected for poster presentation
Merus: Riding The Bispecific Wave In Oncology
Merus stands out in biotech with its innovative Biclonics and Multiclonics platforms, focusing on bispecific and multispecific antibodies, particularly petosemtamab. Strong financials with $724 million cash runway through 2028, allowing strategic R&D investments without immediate capital market pressures. Petosemtamab shows robust clinical data, receiving two FDA Breakthrough Therapy designations, indicating significant potential in treating HNSCC and other cancers.
Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025 at 8:45 a.m. ET.
Merus N.V. (MRUS) Reports Q4 Loss, Lags Revenue Estimates
Merus N.V. (MRUS) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to loss of $1.09 per share a year ago.
Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update
- Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling; expected to be substantially enrolled by YE25
